Vicore Pharma

Vicore Pharma

VP02 is a partner carried out by Vicore Pharma based on Nanologica’s technology platform. The aim of the project is to develop a new drug for the treatment of Idiopathic Pulmonary Fibrosis (IPF), which is a deadly disease where the patients’ lung capacity gradually decreases due to fibrosis of the pulmonary tissue. VP02 is a reformulation of thalidomide, which is an API from the IMiD family (immunomodulatory imide drugs), having both anti-inflammatory and antifibrotic properties. Clinical studies have proven thalidomide to be effective for both the coughing and quality of life for the patients.

VP02 intends to use Nanologica’s technology to deliver the API locally in the lung, which would enable lowering the dose leading the systemic exposure being lowered by 50-85% resulting in fewer side effects.